An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.
The results will be compiled in MM&M's 2017 Agency A-to-Z Directory, the industry's most comprehensive list of healthcare marketing and advertising agencies.
While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.
In this sponsored video series, Marc Iskowitz, MM&M's editor in chief, talks with Tim Armand, co-founder and president, at Health Union about what's next for patients and digital technologies in the healthcare in 2017.
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
Five highly placed insiders in a range of roles and therapeutic categories share secrets to their success and advice that served them well along the way.
AHCA set for vote; J&J halts YouTube ads; approval decisions loom for Sanofi, Roche
Healthcare is sometimes about life or death, but is almost always about quality of life, says the EVP of health system products and strategy.
Here you'll find everything you need to know from MM&M's March 2017 issue, including our healthcare marketers trend report, our deep dive into orphan drugs, and more.
Seven execs from A-list agencies weigh in on talent acquisition and retention.
The Xiidra marketing team attempted to move away from the standard drug commercial to shine in a new market and challenge legacy techniques.
Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD
Eli Lilly claims it only realizes small percentage of list price increases; PBMs become latest target in pricing backlash; AHCA revised
Researchers found that DTC advertising was associated with significant increases in testing and treatment for these drugs
Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study
This program is designed to enable entrepreneurs and biopharma marketers to engage in an intelligent way to explore beyond-the-pill partnerships.
Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.
Per the credit ratings agency, more uninsured Americans will lead to less demand for healthcare services and treatments.
The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Five things for pharma marketers to know: Monday, March 20, 2017
- Novartis aims to bring first oral asthma drug to market in two decades
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Five things for pharma marketers to know: Tuesday, March 21, 2017
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media